$UTMD
Utah Medical Products Inc

2023 Q3 Form 10-Q Financial Statement

#000181188423000017 Filed on August 11, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $12.51M $12.87M
YoY Change -3.47% -4.19%
Cost Of Revenue $5.146M $5.127M
YoY Change 7.91% -2.84%
Gross Profit $7.359M $7.739M
YoY Change -10.1% -5.05%
Gross Profit Margin 58.85% 60.15%
Selling, General & Admin $3.252M $3.181M
YoY Change 10.88% 7.5%
% of Gross Profit 44.19% 41.1%
Research & Development $138.0K $133.0K
YoY Change 23.21% -1.48%
% of Gross Profit 1.88% 1.72%
Depreciation & Amortization $1.770M $1.766M
YoY Change 2.19% 0.11%
% of Gross Profit 24.05% 22.82%
Operating Expenses $3.390M $3.314M
YoY Change 11.33% 7.11%
Operating Profit $3.969M $4.425M
YoY Change -22.8% -12.5%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $812.0K $747.0K
YoY Change 310.1% 426.06%
Pretax Income $4.781M $5.172M
YoY Change -10.45% -0.52%
Income Tax $846.0K $972.0K
% Of Pretax Income 17.7% 18.79%
Net Earnings $3.935M $4.200M
YoY Change -8.06% 2.36%
Net Earnings / Revenue 31.47% 32.64%
Basic Earnings Per Share $1.08 $1.16
Diluted Earnings Per Share $1.08 $1.15
COMMON SHARES
Basic Shares Outstanding 3.630M shares 3.628M shares
Diluted Shares Outstanding 3.639M shares 3.639M shares

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $88.20M $84.62M
YoY Change 26.89% 27.78%
Cash & Equivalents $88.21M $84.62M
Short-Term Investments
Other Short-Term Assets $442.0K $467.0K
YoY Change 14.21% 3.09%
Inventory $9.709M $10.12M
Prepaid Expenses
Receivables $3.487M $3.604M
Other Receivables $0.00 $0.00
Total Short-Term Assets $101.8M $98.81M
YoY Change 20.9% 25.15%
LONG-TERM ASSETS
Property, Plant & Equipment $10.35M $10.54M
YoY Change 5.01% 3.64%
Goodwill $13.42M $13.68M
YoY Change 4.3% 2.09%
Intangibles $5.626M $7.451M
YoY Change -49.05% -43.59%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $29.40M $31.67M
YoY Change -13.97% -14.86%
TOTAL ASSETS
Total Short-Term Assets $101.8M $98.81M
Total Long-Term Assets $29.40M $31.67M
Total Assets $131.2M $130.5M
YoY Change 10.83% 12.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $511.0K $1.336M
YoY Change -60.36% 63.33%
Accrued Expenses $3.666M $3.808M
YoY Change -26.39% 5.16%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.177M $5.144M
YoY Change -33.37% 15.88%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.256M $1.257M
YoY Change -25.01% -24.96%
Total Long-Term Liabilities $1.256M $1.257M
YoY Change -25.01% -24.96%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.177M $5.144M
Total Long-Term Liabilities $1.256M $1.257M
Total Liabilities $7.541M $8.714M
YoY Change -26.26% 0.41%
SHAREHOLDERS EQUITY
Retained Earnings $135.1M $132.3M
YoY Change 10.3% 10.89%
Common Stock $557.0K $468.0K
YoY Change 492.55% 1200.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $123.7M $121.8M
YoY Change
Total Liabilities & Shareholders Equity $131.2M $130.5M
YoY Change 10.83% 12.33%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income $3.935M $4.200M
YoY Change -8.06% 2.36%
Depreciation, Depletion And Amortization $1.770M $1.766M
YoY Change 2.19% 0.11%
Cash From Operating Activities $5.120M $4.913M
YoY Change -8.39% 1.68%
INVESTING ACTIVITIES
Capital Expenditures $190.0K $320.0K
YoY Change -159.19% -244.14%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$190.0K -$320.0K
YoY Change -40.81% 44.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.030M -1.010M
YoY Change -0.19% -71.56%
NET CHANGE
Cash From Operating Activities 5.120M 4.913M
Cash From Investing Activities -190.0K -320.0K
Cash From Financing Activities -1.030M -1.010M
Net Change In Cash 3.900M 3.583M
YoY Change -7.93% 238.34%
FREE CASH FLOW
Cash From Operating Activities $5.120M $4.913M
Capital Expenditures $190.0K $320.0K
Free Cash Flow $4.930M $4.593M
YoY Change -16.58% -9.12%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-12575
dei Entity Registrant Name
EntityRegistrantName
UTAH MEDICAL PRODUCTS INC
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
UT
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0342734
dei Entity Address Address Line1
EntityAddressAddressLine1
7043 South 300 West
dei Entity Address City Or Town
EntityAddressCityOrTown
Midvale
dei Entity Address State Or Province
EntityAddressStateOrProvince
UT
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
84047
dei City Area Code
CityAreaCode
801
dei Local Phone Number
LocalPhoneNumber
566-1200
dei Security12b Title
Security12bTitle
Common stock, $0.01 par value
dei Trading Symbol
TradingSymbol
UTMD
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
3629525 shares
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
84619000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
75052000 usd
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3604000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5538000 usd
CY2023Q2 us-gaap Inventory Net
InventoryNet
10117000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
8814000 usd
CY2023Q2 us-gaap Other Assets Current
OtherAssetsCurrent
467000 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
515000 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
98807000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
89919000 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10541000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10224000 usd
CY2023Q2 us-gaap Goodwill
Goodwill
13676000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
13354000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
54250000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
52755000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
46799000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
42378000 usd
CY2023Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
7451000 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
10377000 usd
CY2023Q2 us-gaap Assets
Assets
130475000 usd
CY2022Q4 us-gaap Assets
Assets
123874000 usd
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1336000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1218000 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3808000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4742000 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
5144000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5960000 usd
CY2023Q2 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
1370000 usd
CY2022Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
1514000 usd
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1257000 usd
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1256000 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
315000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
341000 usd
CY2023Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
628000 usd
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
549000 usd
CY2023Q2 us-gaap Liabilities
Liabilities
8714000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
9620000 usd
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3629000 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3629000 shares
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
150000 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
5172000 usd
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3628000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3628000 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
36000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
36000 usd
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Before Tax1
AccumulatedOtherComprehensiveIncomeLossBeforeTax1
-10986000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Before Tax1
AccumulatedOtherComprehensiveIncomeLossBeforeTax1
-12039000 usd
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
432000 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
251000 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
132279000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
126006000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
121761000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
114254000 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
130475000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
123874000 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12866000 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
13428000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25386000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25752000 usd
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5127000 usd
CY2022Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5277000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
9805000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
10069000 usd
CY2023Q2 us-gaap Gross Profit
GrossProfit
7739000 usd
CY2022Q2 us-gaap Gross Profit
GrossProfit
8151000 usd
us-gaap Gross Profit
GrossProfit
15581000 usd
us-gaap Gross Profit
GrossProfit
15683000 usd
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3181000 usd
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2959000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6440000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5846000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
133000 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
135000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
277000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
258000 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
3314000 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
3094000 usd
us-gaap Operating Expenses
OperatingExpenses
6717000 usd
us-gaap Operating Expenses
OperatingExpenses
6104000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
4425000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
5057000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
8864000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
9579000 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
747000 usd
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
142000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1428000 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
5199000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
10292000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
9729000 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
972000 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1096000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1878000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2091000 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
4200000 usd
CY2022Q2 us-gaap Profit Loss
ProfitLoss
4103000 usd
us-gaap Profit Loss
ProfitLoss
8414000 usd
us-gaap Profit Loss
ProfitLoss
7638000 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.16
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.32
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.09
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.15
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.12
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.31
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.09
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3628000 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3643000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3628000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3649000 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3639000 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3650000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3638000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3658000 shares
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
0 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
0 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
0 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
0 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
504000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2298000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1053000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2804000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
4704000 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1805000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
9467000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
4834000 usd
us-gaap Profit Loss
ProfitLoss
8414000 usd
us-gaap Profit Loss
ProfitLoss
7638000 usd
us-gaap Depreciation
Depreciation
310000 usd
us-gaap Depreciation
Depreciation
302000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3207000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3257000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-26000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
26000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
26000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
26000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-137000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-286000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
100000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
83000 usd
us-gaap Deferred Tax Expense From Stock Options Exercised
DeferredTaxExpenseFromStockOptionsExercised
9000 usd
us-gaap Deferred Tax Expense From Stock Options Exercised
DeferredTaxExpenseFromStockOptionsExercised
0 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2044000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-102000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1245000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
930000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
47000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
114000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
64000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-991000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-357000 usd
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
3414000 usd
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
2240000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
11828000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
9878000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
363000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
450000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
9000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-363000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-459000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
81000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
23000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
2495000 usd
us-gaap Payments Of Dividends
PaymentsOfDividends
2140000 usd
us-gaap Payments Of Dividends
PaymentsOfDividends
1060000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2059000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-3532000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
161000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-637000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
9567000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5250000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
75052000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
60974000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
84619000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
66224000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
2546000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
2467000 usd
us-gaap Interest Paid
InterestPaid
0 usd
us-gaap Interest Paid
InterestPaid
0 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
114254000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
21000 usd
CY2023Q1 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
50000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
549000 usd
CY2023Q1 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
1070000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
4214000 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
118018000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
60000 usd
CY2023Q2 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
50000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
504000 usd
CY2023Q2 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
1071000 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
4200000 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
121761000 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
107138000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
19000 usd
CY2022Q1 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
43000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-506000 usd
CY2022Q1 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
1060000 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
3534000 usd
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
109168000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4000 usd
CY2022Q2 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
40000 usd
CY2022Q2 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
-2495000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2298000 usd
CY2022Q2 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
1051000 usd
CY2022Q2 us-gaap Profit Loss
ProfitLoss
4103000 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
107471000 usd
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3638000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3658000 shares
CY2023Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2520000 usd
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1896000 usd
CY2023Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
1432000 usd
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1193000 usd
CY2023Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
6165000 usd
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
5725000 usd
CY2023Q2 us-gaap Inventory Net
InventoryNet
10117000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
8814000 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
50000 usd
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
40000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
100000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
83000 usd
CY2022Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
0 usd
CY2023Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
0 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12866000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25386000 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
4200000 usd
CY2022Q2 us-gaap Profit Loss
ProfitLoss
4103000 usd
us-gaap Profit Loss
ProfitLoss
8414000 usd
us-gaap Profit Loss
ProfitLoss
7638000 usd
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3628000 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3643000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3628000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3649000 shares
CY2023Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
11000 shares
CY2022Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
7000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
10000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
9000 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3639000 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3650000 shares
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.16
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.32
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.09
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.15
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.12
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.31
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.09

Files In Submission

Name View Source Status
0001811884-23-000017-index-headers.html Edgar Link pending
0001811884-23-000017-index.html Edgar Link pending
0001811884-23-000017.txt Edgar Link pending
0001811884-23-000017-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
report.css Edgar Link pending
Show.js Edgar Link pending
utmd-20230630.htm Edgar Link pending
utmd-20230630.xsd Edgar Link pending
utmd_ex31z1.htm Edgar Link pending
utmd_ex31z2.htm Edgar Link pending
utmd_ex32z1.htm Edgar Link pending
utmd_ex32z2.htm Edgar Link pending
utmd-20230630_def.xml Edgar Link unprocessable
utmd-20230630_pre.xml Edgar Link unprocessable
utmd-20230630_lab.xml Edgar Link unprocessable
utmd-20230630_htm.xml Edgar Link completed
utmd-20230630_cal.xml Edgar Link unprocessable